Tickers featured: ALPMY, AUXL, AZN, BSTC, CORT, DNDN, DSCO, DYAX, GSK, KG, MDVN, MYGN, PDLI, PFE, RDEA
, SGYP, SVNT, TRGT.
Limited Tenders are invited for Procurement Of Pump Rdea
Tickers featured: ALXN, AUXL, AZN, CLDX, DNDN, GSK, KERX, MDVN, MRK, NKTR, PFE, POZN, RDEA
26 May 2011 - US Ardea Biosciences Inc (NASDAQ: RDEA
) said yesterday that additional encouraging clinical and preclinical results from its development programme of lesinurad, its lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in London, UK.
20 January 2011 - US Ardea Biosciences Inc (NASDAQ: RDEA
) said yesterday it has commenced an underwritten public offering of an aggregate of 2.5m shares of its common stock.
7 January 2011 - US-based biotechnology company Ardea Biosciences Inc (NASDAQ: RDEA
) reported yesterday positive, preliminary, top-line results from its Phase IIb study of RDEA594 in combination with the current standard of care for the treatment of gout, allopurinol.
3 November 2010 - US Ardea Biosciences Inc (NASDAQ: RDEA
) said yesterday it has been awarded a USD733,438 (EUR523,000) grant from the Department of Health and Human Services (HHS) under the recently enacted Patient Protection and Affordable Care Act.